Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Hallmarks of aging
Video summary

Panel on translating geroscience into FDA-satisfying aging trials

A panel discusses how geroscience evidence from animals and growing human data could become an approved therapy, focusing on trial design, endpoints, regulation and funding. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The description says the geroscience hypothesis has strong support in animal models and growing human data. [1]

  2. The panel covers lessons from clinical efforts, including the long road of the TAME trial. [1]

  3. The panel asks how a trial targeting aging can be structured to satisfy the FDA. [1]

The source at a glance

Study type / format
Video description of a panel discussion
Population / context
A conference panel: moderator Hanadie Yousef and panelists Stephen Kritchevsky, David Gobel and Matt Kaeberlein
Summary based on
Creator description
Original publication
August 20, 2026

Panel topic: from geroscience evidence to approved therapy

The description says the geroscience hypothesis has strong support in animal models and a growing body of human data. The panel treats the step to an approved therapy as a different problem. It names trial design, endpoint selection, regulatory strategy and money as the issues involved.

Supporting source [1]

TAME trial and structuring a trial to satisfy the FDA

The panel covers what the field has learned from clinical efforts so far. The description highlights the long road of the TAME trial and asks how a trial targeting aging can be structured to satisfy the FDA. It also asks what should be prioritized to get a first intervention across the finish line.

Supporting source [1]

Description scope: panel format, no results reported

The description names moderator Hanadie Yousef and panelists Stephen Kritchevsky, David Gobel and Matt Kaeberlein. It presents the session as a discussion of lessons, trial structure and priorities. It reports no trial results, effect sizes or outcomes, so none can be stated here.

Supporting source [1]

How to interpret this

Only the video description was available; the video and transcript were not reviewed. The description reports no trial results, effect sizes or outcomes, and the panel's discussion content is not summarized here.

Based on the creator’s description; the full video and transcript were not analyzed.

Source & supporting passages

[1]
H-SPAN Summit D.C. 2026 | Translating Geroscience from Lab to Patients

The Alliance for Longevity Initiatives · youtube.com · August 20, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    strong support in animal models
  2. Finding 2 ↑

    the long road of the TAME trial
  3. Finding 3 ↑

    structured to satisfy the FDA

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…